Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halberd Corp (OP:HALB)

0.0008 -0.0002 (-20.00%)
Streaming Delayed Price Updated: 10:56 AM EDT, May 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Halberd Corp

< Previous 1 2 3 4 5 Next >
News headline image
Halberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans Annually
JACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC PINK:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease Antigens
Tau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases. JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC PINK:HALB) has demonstrated the... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture
Tau has been shown to be important in the development of Alzheimer's Disease. Eradication of Tau accomplished without reducing levels of non-target cytokine. JACKSON CENTER, PA / ACCESSWIRE / February... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd CEO Letter: 2021 Year-End & 2022 Outlook
JACKSON CENTER, PA / ACCESSWIRE / January 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) First of all I want to wish all of our shareholders and constituents a Very... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases
JACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC PINK:HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Corporation Now an Official US Government Contractor
Halberd to bid on Additional Federal Contracts with the Federal Government JACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation (OTC PINK:HALB) is now registered with the Federal... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases
Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC Pink:HALB) has been able to successfully eliminate... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases
JACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in... 
From Halberd Corporation
Via AccessWire
News headline image
Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTE
JACKSON CENTER, PA / ACCESSWIRE / December 6, 2021 / Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
News headline image
Halberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer’s Disease
JACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF)... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves
JACKSON CENTER, PA / ACCESSWIRE / November 8, 2021 / Halberd Corporation (OTC PINK:HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease
Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease. JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
JACKSON CENTER, PA / ACCESSWIRE / October 25, 2021 / Halberd Corporation (OTC PINK:HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity Cure
JACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC PINK:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd and GTX Corp. Sign Scientific Collaboration and Reseller Agreement
GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer's Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd's VitaShieldMaxTM Immune... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation CEO Letter
JACKSON CENTER, PA / ACCESSWIRE / October 7, 2021 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC PINK:HALB) This past quarter, Halberd has made some very significant and unparalleled... 
From Halberd Corporation
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
News headline image
Halberd's VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
JACKSON CENTER, PA / ACCESSWIRE / October 5, 2021 / Halberd Corporation (OTC PINK:HALB) announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
Agreement To Advance Healthcare Diagnostic Technologies JACKSON CENTER, PA / ACCESSWIRE / September 22, 2021 / Halberd Corp. (OTC PINK:HALB) and heliosDx, a wholly owned company of RushNet, Inc. (OTC... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd's Treatment Eradicates Primary Building Block of Alzheimer’s Disease
JACKSON CENTER, PA / ACCESSWIRE / September 13, 2021 / Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer's Disease from... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & Acquisitions
JACKSON CENTER, PA / ACCESSWIRE / September 8, 2021 / Halberd Corporation (OTC PINK:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions.... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding Results
JACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow Aging
JACKSON CENTER, PA / ACCESSWIRE / August 25, 2021 / Halberd Corporation (OTC PINK:HALB) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office,... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's Disease
JACKSON CENTER, PA / ACCESSWIRE / August 23, 2021 / Halberd Corp. (OTC PINK:HALB) announced filing a U. S. joint provisional patent application, "Treating Alzheimer's Disease Utilizing Extracorporeal... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
News headline image
Halberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!
JACKSON CENTER, PA / ACCESSWIRE / August 18, 2021 / Halberd Corporation's (OTC PINK:HALB) Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN
JACKSON CENTER, PA / ACCESSWIRE / August 16, 2021 / Halberd Corporation's (OTC PINK:HALB) research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted Nephrologist
JACKSON CENTER, PA / ACCESSWIRE / August 11, 2021 / Halberd Corporation (OTC PINK:HALB) today confirmed the addition of Dr. Ned Kronfol as a member of its Scientific Advisory Board. Dr. Kronfol is... 
From Halberd Corporation
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product Shipped
JACKSON CENTER, PA / ACCESSWIRE / August 9, 2021 / Halberd Corporation (OTC PINK:HALB) reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant,... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property Regulatory Compliance
News headline image
Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished"
A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE JACKSON CENTER, PA / ACCESSWIRE / July 28, 2021 / Halberd Corporation (OTC... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
News headline image
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy
JACKSON CENTER, PA / ACCESSWIRE / July 22, 2021 / Halberd Corporation (OTC PINK:HALB) confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer's Disease (AD) antibodies, Tau... 
From Halberd Corporation
Via AccessWire
Topics Intellectual Property
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.